Akero Therapeutics, Inc.
AKRO
Kedudukan dalam Saham
#3718
Akero Therapeutics, Inc. is a biopharmaceutical firm dedicated to addressing... Akero Therapeutics, Inc. is a biopharmaceutical firm dedicated to addressing cardio-metabolic disorders, with a specific focus on nonalcoholic steatohepatitis (NASH). Its primary objective is the creation of therapeutic agents aimed at re-establishing metabolic equilibrium and enhancing overall well-being. The company's flagship investigational drug is efruxifermin (EFX), a synthetic analog of fibroblast growth factor 21. EFX is designed to shield cells from stress and modulate the systemic metabolism of fats, carbohydrates, and proteins throughout the body. This promising compound is currently undergoing evaluation in a Phase 2a clinical investigation, known as the BALANCED study, for individuals diagnosed with biopsy-confirmed NASH. Originally established as Pippin Pharmaceuticals, Inc., the organization rebranded as Akero Therapeutics, Inc. in May 2018. Founded in 2017, Akero Therapeutics maintains its corporate headquarters in South San Francisco, California.
Harga Saham
$54.65
Disegerakkan terakhir: 2025-12-09
Modal Pasaran
$4.50B
Perubahan (1 hari)
0.00%
Perubahan (1 tahun)
1.94%
Negara
US
Perdagangan Akero Therapeutics, Inc. (AKRO)
Kategori
Healthcare
Sejarah harga saham bagi Akero Therapeutics, Inc. (AKRO)
Harga penutupan tertinggi: $54.59 pada 2025-12-01
Harga penutupan terendah: $18.95 pada 2019-06-01
Harga penutupan terendah: $18.95 pada 2019-06-01
Sejarah harga saham Akero Therapeutics, Inc. dari 2019 hingga 2026
Prestasi harga saham tahunan
| Tahun | Prestasi |
|---|---|
| 2026 (TTM) | -0.66% |
| 2025 | 84.69% |
| 2024 | 39.17% |
| 2023 | -53.49% |
| 2022 | 118.99% |
| 2021 | -23.63% |
| 2020 | 26.67% |
| 2019 | 0.00% |
Harga saham bagi syarikat atau pesaing serupa
| Syarikat | Harga saham | Perubahan 1thn% | Negara |
|---|---|---|---|
| $527.18 | 23.62% |
US
|
|
| $251.29 | 835.90% |
US
|
|
| $137.07 | -4.31% |
AU
|
|
| $890.85 | 9.42% |
NL
|
|
| $752.87 | 7.01% |
CH
|
